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Background information. The BOR (branchio-oto-renal) syndrome is a dominant disorder most commonly caused
by mutations in the EYA1 (Eyes Absent 1) gene. Symptoms commonly include deafness and renal anomalies.
Results. We have used the embryos of the frog Xenopus laevis as an animal model for early ear development to
examine the effects of different EYA1 mutations. Four eya1 mRNAs encoding proteins correlated with congenital
anomalies in human were injected into early stage embryos. We show that the expression of mutations associated
with BOR, even in the presence of normal levels of endogenous eya1 mRNA, leads to morphologically abnormal
ear development as measured by overall otic vesicle size, establishment of sensory tissue and otic innervation.
The molecular consequences of mutant eya1 expression were assessed by QPCR (quantitative PCR) analysis and
in situ hybridization. Embryos expressing mutant eya1 showed altered levels of multiple genes (six1, dach, neuroD,
ngnr-1 and nt3) important for normal ear development.
Conclusions. These studies lend support to the hypothesis that dominant-negative effects of EYA1 mutations may
have a role in the pathogenesis of BOR.
Introduction
The BOR (branchio-oto-renal) syndrome in humans
is an autosomal dominant disorder characterized by
branchial cleft abnormalities, otic developmental de-
fects and renal malformations. All of the causes of
BOR remain to be determined but mutations in sev-
eral different genes have been implicated. To date,
autosomal dominant mutations in the EYA1 (Eyes
Absent 1) gene (Abdelhak et al., 1997b) are the most
common genetic cause of BOR. EYA1 is the human
1To whom correspondence should be addressed (email
daniel-weeks@uiowa.edu).
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Abbreviations used: BOR, branchio-oto-renal; DACH, dachshund; DIG,
digoxigenin; DMED, dimethylethylenediamine; EYA1,E y e sA b s e n t1 ;G F P ,
green ﬂuorescent protein; GST, glutathione transferase; HAD, haloacid
dehalogenase; HRP, horseradish peroxidase; QPCR, quantitative PCR;
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THF, tetrahydrofuran.
homologue of the Drosophila gene eya (eyes absent),
in which null mutations result in eyeless ﬂy embryos
due to apoptotic loss of eye disc cells (Bonini et al.,
1993). Subsequent studies reported homologues of
the eya gene in vertebrates (Duncan et al., 1997)
and the rescue of the Drosophila phenotype with cop-
ies of human and murine EYA1 conﬁrmed functional
similarity (Bui et al., 2000).
The multiple members of the EYA gene family
have a relatively divergent N-terminal activation
domain coupled with a conserved C-terminal
EYA domain. Although EYA1 protein does not
bind directly to DNA, the EYA domain interacts
with other DNA-binding proteins. Transcription
factors SIX (sine oculis) and DACH (dachshund) are
among the proteins that can form a complex with
EYA1,andtranslocationofEYA1fromthecytoplasm
into the nucleus seems to be SIX dependent (Ohto
et al., 1999). EYA1 is a member of the phosphatase
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subfamilyoftheHAD(haloaciddehalogenase)super-
family and can act as a protein tyrosine phosphatase
(Rayapureddiet al.,2003;Tootleet al.,2003);muta-
tions that compromise this enzymatic activity alter
its ability to serve as a transcription cofactor (Tootle
et al., 2003; Mutsuddi et al., 2005).
TrackingthedevelopmentalconsequencesofEYA1
mutations has taken advantage of previous studies in
a number of model organisms including studies
in Xenopus laevis. Initial characterization of the
Xenopus homologue of EYA1 revealed 85% iden-
tity at the amino acid level with the human form
of the protein (David et al., 2001). Xenopus eya1 ex-
pression begins during early gastrulation and contin-
ues throughout development. Early embryonic ex-
pression is similar to that seen during mammalian
development, including expression in all neurogenic
placodes and placodally derived structures with the
exception of the lens (David et al., 2001). Of particu-
lar relevance to the work reported here is the expres-
sionofeya1intheoticplacodeandthedevelopingear
(Bane et al., 2005). Recently, Schlosser et al. (2008)
probed early developmental defects that arose after
morpholino-targeted reduction of eya1 protein. They
came to the conclusion that eya1 was required for
normal pre-placodal ectoderm and placodal neuron
formation. Their studies were consistent with con-
clusions drawn from studies on Eya1 in mutant mice
(Zou et al., 2004, 2008).
The human phenotype associated with different
EYA1 mutations can vary, and over eighty mutations
have been reported (Orten et al., 2008). We note
that as more detailed information about the EYA1
gene became available, current numerical designa-
tions found in the Human Gene Mutation Database
no longer match historical designations. In this pa-
per, we chose to study mutations representative of a
rangeofphenotypes.Forexample,E363Kwasorigin-
ally designated E330K (Azuma et al., 2000) and is
associated with ocular defects without BOR; G426S
[originally G393S (Azuma et al., 2000)] is associated
with BOR and ocular defects; R440Q [originally
R407Q (Kumar et al., 1997) and one of the most
common BOR mutations (Orten et al., 2008)] and
L505R [originally L472R (Abdelhak et al., 1997a)]
are associated with BOR without ocular defects.
Others have examined these mutations in an attempt
to understand the molecular mechanisms that lead to
syndromic consequences. Although the results are
not uniformly consistent they do provide some inter-
esting observations. For example, in vitro and tissue
cultureexperimentswithE363K,G426SandL505R
showedthatthesemutantproteinspreservetheirabil-
ity to translocate to the nucleus (Buller et al., 2001)
in a Six protein-dependent manner although E358K
and L505R fail to bind directly to Six1 (Buller et al.,
2001; Rayapureddi and Hegde, 2006). This suggests
that an additional intermediate may be required for
Six1-dependent transport of Eya1 to the nucleus.
When assayed as GST (glutathione transferase) fu-
sions E363K, G426S and L505R mutants have re-
duced phosphatase activity; however, when G426S
was analysed in its non-fusion form it had wild-
type phosphatase activity (Mutsuddi et al., 2005;
Rayapureddi and Hegde, 2006). These ﬁndings in-
dicate that phosphatase activity alone may not guar-
antee normal function or, alternatively, that factors
that affect folding or association with other pro-
teins (as may occur with the GST fusions) may mask
phosphataseactivity.StudiesinDrosophila(Mutsuddi
et al.,2005)concludedthatE363KandG426Scould
induceectopiceyestructuresbutthatE363K,G426S
and L505R mutations were incapable of fully res-
cuing an eya-null mutation. However, all of these
mutations compromised the transcriptional activa-
tion of a tested target gene.
We are particularly interested in how EYA1 muta-
tionsalterearlyeardevelopmentanduseXenopusem-
bryos as a model. These embryos offer several advant-
ages. The ﬁrst is that mRNA encoding mutant forms
of eya1 can be directly injected into embryos. mRNA
injection endows embryos with the capacity to pro-
ducethemutantproteinwithouthavingtocreateand
maintain stocks of animals with the mutations that
are being studied. Secondly, for bilateral structures
like ears, one-sided injections are easily performed
by injecting only one of the two blastomeres at the
two-cell stage. This allows one side of the embryo to
serve as a control, while the other side is used to
examine changes in development. Finally, unlike
mammals, fertilization and development are external
in Xenopus, simplifying observation of the embryos.
As noted above, BOR is an autosomal dominant
disorder. Haploinsufﬁciency is one of the mechan-
isms by which genetic mutations result in auto-
somal dominant disorders. The BOR/EYA1 path-
way has been proposed to fall into this class (Zhang
et al., 2004; Orten et al., 2008). Although it is clear
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Figure 1 Comparison of the partial amino acid sequence
of human and Xenopus eya1
Amino acid substitutions associated with BOR and ocular de-
fects are in larger boldface font. Italic letters indicate con-
served motifs characteristic of HAD family proteins. (This Fig-
ure is modiﬁed from Rayapureddi and Hegde, 2006.) Mutation
designations for human (hEYA1) as cited in the Human Gene
Mutation Database (http://www.hgmd.cf.ac.uk/ac/index.php)
are above the aligned sequences, and the corresponding
numbering for Xenopus (Xeya1) is below them. OD, ocular
defects.
that reducing the amount of EYA1 product leads to
developmental defects (Schlosser et al., 2008; Zou
et al., 2008), the possibility that these mutations
also act in a dominant-negative fashion remains an
open question. The experiments described here ex-
plore whether the BOR-causing mutations mediate
their effect solely via haploinsufﬁciency or whether a
dominant-negative effect is also possible. We also ex-
amine whether early, but developmentally transient,
expression of aberrant eya1 protein irrevocably alters
otic development. We report here that the presence
of mRNA encoding mutant eya1 compromises the
normal formation of the otic system by affecting
the structure, innervation and gene expression.
Results
Expression of eya1 mutants after injection of
mRNA into Xenopus embryos
Three of the four eya1 mutations used in the present
study are associated with the BOR syndrome in hu-
mans. Figure 1 shows the alignment of human and
the slightly smaller Xenopus protein in the region
where the mutations occur. As described in the Ma-
terialsandmethodssection,an11-amino-acidT7epi-
tope was incorporated into the N-terminal region of
eya1proteinsencodedbymRNAsusedinthepresent
study. We chose this epitope to distinguish the pro-
Figure 2 Expression of eya1 after injection of mRNA
encoding eya1 proteins into Xenopus embryos
Embryos were injected (inj.) with 250 ng of mRNA, and protein
isolated from two embryos was loaded on to each lane. (A)
A Western blot that shows that mRNAs encoding eya1 and
four mutant variants produce detectable protein in stage 12
embryos. Anti-T7 antibody was used to detect proteins. (B)A
Western blot that shows that eya1 protein made from injected
mRNA persists through stage 41. Anti-T7 antibody was used
to detect proteins. NI, non-injected control.
tein made by injected mRNA from that made by
endogenous eya1 mRNA, and because the antibodies
recognizing the T7 epitope have low background re-
activitytoproteinsmadeduringXenopusembryogen-
esis.InFigure2,weprovideevidencethatmRNAfor
alloftheproteinsbeingusedinthepresentstudywere
translated after injection into Xenopus embryos. De-
velopmental staging (Nieuwkoop and Faber, 1967)
and landmarks of otic development (Schlosser and
Northcutt, 2000; Bever et al., 2003; Bane et al.,
2005; Quick and Serrano, 2005) noted in this ma-
nuscript include stage 12 (mid-gastrula), stage 16
(mid-neural fold), stage 23 (the ﬁrst slight depres-
sion of the otic placode) and stage 27 (otic vesicle
closed). From stage 32 to stage 40, the ear grows,
hair cells begin to develop and the medial and lat-
eral aspects of the sensory regions of the ear become
distinct. By stage 47 the membranous labyrinth of
the ear is almost fully formed although the devel-
opment of auditory components continues through
metamorphosis (Fritzsch, 1988).
All of the proteins could be detected using an
anti-eya1antibodyprovidedbyDrGerhardSchlosser
(Martin Ryan Institute, National University of
Ireland, Galway, Ireland; results not shown); how-
ever, the production of protein from injected mRNA
was more easily detected by reactivity to the T7
epitope. Proteins were readily detected by stage 12
(Figure 2A), approximately the time the endogenous
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eya1 gene is expressed (David et al., 2001). When
we compared the levels of protein expressed in Fig-
ure 2(A), we detected a less than 2-fold variation
in expression. We detected the expression of protein
from injected mRNA for many hours. For example
inFigure2(B),eya1proteininembryosinjectedwith
mRNAwasdetectedthroughtostage41.Wedonote
thatthemRNAinjectedintheseassaysisdistributed
throughout the embryo, whereas endogenous eya1
mRNA is spatially restricted (David et al., 2001).
mRNA encoding epitope-tagged wild-type eya1
produces functional protein
We next established that the epitope-tagged protein
made by injected mRNA was capable of directing
eya1-controlled processes. In the studies presented
here, we routinely assayed otic development using
embryos ﬁxed for whole mount analysis at stages 32
and 40. For morphological assessment each embryo
was exposed to antibodies to detect acetylated
α-tubulin to mark sensory and neural tissue. All
embryos were also treated with phalloidin to detect
F-actin to provide a more global view of surrounding
tissues. An example of the approach is seen in
Figures 3(A)–3(E) and 3(G) (images from stage 32)
and Figures 3(F) and 3(H) (the otic section of stage
40). Tubulin is readily seen (Figures 3A, 3B, 3E
and 3F) in the spcd (spinal cord), developing nerves
(Figures 3E and 3F, cranial nerves V, VII and VIII),
sensory patches (Figures 3E and 3F, labelled Ost)
andthe neurites matching the sensory patches to the
VIII cranial nerve (arrowheads in Figures 3E and
3F). Acetylated tubulin is also present in ciliated
epidermal cells (ce) that are not relevant for our
study on otic development. Bracketed areas in
Figures 3(A) and 3(C) indicate the regions that
were imaged for Figures 3(B) and 3(D). Bracketed
regions in Figures 3(B) and 3(D) indicate the region
enlarged in Figures 3(E) and 3(G). F-actin detection
with phalloidin allows a strong contrast between
the cells that form the otic vesicle and the hollow
chamber within (marked vOt) in Figures 3(D), 3(G)
and 3(H). Because otic sensory tissue is derived
from otic epithelium any changes in development
of the otic vesicle might compromise sensory tissue
development. When examining treated embryos
for developmental defects, we use images like
those in Figure 3 to assess the size of the otic
vesicle, the approximate number and distribution of
Figure 3 Detection of otic development in Xenopus
embryos
Oticdevelopmentwasmonitoredbyﬂuorescenceusingwhole
mount immunohistochemistry to detect acetylated tubulin (A,
B, E, F) and F-actin using phalloidin (C, D, G, H). (A–E, G)
These Figures show progressively increased magniﬁcation of
a stage 32 embryo, with bracketed regions indicating the re-
gion shown in the next magniﬁcation. (A, C) These Figures
werevisualizedusingaﬂuorescentmicroscopeandareshown
in lateral view with heads on the right. (B, D) These Fig-
ures were visualized through the dorsal–ventral plane using
a confocal microscope with the anterior at the top of the im-
ages. (E–H) These Figures are confocal sections through the
dorsal–lateral prospect. The anterior of the embryo is towards
the top of each image. (F, H) These Figures are the otic region
from a stage 40 embryo. The spcd, ciliated epithelial cells (ce),
otic sensory tissue (Ost), neurites associated with otic sens-
ory tissue (arrowheads) and cranial nerves (V, VII and VIII) are
noted on panels detecting tubulin; the otic vesicle (vOt), eye
and cement gland (cg) are noted on panels detecting F-actin.
Scale bars in (B, D, E, F, G, H), 50 μm.
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Figure 4 Oligonucleotide-mediated loss of eya1 and rescue by injection of eya1 mRNA
(A) DMED-modiﬁed oligonucleotides complementary to Xenopus eya1 reduce the levels of eya1 mRNA.Eya1 mRNA was assayed
from non-injected embryos (NI), embryos injected with 1 ng of a control oligonucleotide (C) or 1, 0.5 or 0.25 ng of anti-eya1
oligonucleotide. (B) Injection of 1 ng of anti-eya1 oligonucleotide into one side of the embryo reduces the level of endogenous
eya1 and six1 mRNAs shown by in situ hybridization. (C) Reduction of eya1 correlates with inability to form a proper otocyst, as
assayed by whole mount immunohistochemical detection of tubulin and F-actin by confocal microscopy along the dorsal–lateral
plane. Both six1 expression and normal otocyst formation are rescued by co-injection of oligonucleotide with 250 pg of rescue
mRNA encoding T7–eya1 protein. The otic vesicle (vOt) and facial epibranchial placode (epVII) are identiﬁed in (B). In (C), otic
sensory tissue (Ost), cranial nerves (V, VII and VIII) and neurites leading to the VIII nerve (arrowheads) are labelled. Scale bars on
in situ hybridization images, 200 μm; scale bars on confocal images, 50 μm. Inj. injected.
sensory patches and the connections of the
sensory patches to the VIII cranial nerve.
Functionality of T7-epitope-tagged eya1 proteins
derivedfrominjectedmRNAwastestedintrialsthat
attempted to rescue embryos depleted of endogenous
eya1 via antisense oligonucleotides. There are sev-
eral possible approaches that use oligonucleotides to
alterproteinproductionofaspeciﬁctranscript(Dagle
and Weeks, 2001). Schlosser et al. (2008) used mor-
pholinoantisenseoligonucleotidestoinvestigateeya1
loss. Most commonly, morpholinos work by block-
ing translation, so evidence of their action must be
determined by analysis of protein loss. In our
alternative approach, we used oligonucleotides that
have blocks of DMED (dimethylethylenediamine)-
modiﬁed internucleoside linkages near their 3 -a n d
5 -ends that stabilize the oligonucleotide and also
have a series of at least ﬁve phosphodiester linkages
to direct targeted RNaseH-mediated degradation of
endogenousmRNA(Dagleet al.,2000).Fortheeya1
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Table 1 Survival of Xenopus embryos after injection treatment
Embryos [except non-injected controls (NI)] were injected with a mix of indicated eya1 mRNA
and GFP mRNAs. Four different trials were included in the analysis. All survival analyses
started with the indicated number of embryos at stage 10 (early gastrula stage).
Survival (%)
Stage NI eya1 E358K G421S L500R R435Q GFP
32 97 77 84 82 79 74 73
40 96 65 60 50 54 49 65
47 96 62 53 38 40 35 62
Embryos analysed (n) 210 276 250 251 287 281 273
mRNA we found that 1 ng of a DMED anti-eya1
oligonucleotide reduced the endogenous level of
mRNA by over 90% (Figure 4A), while a control
oligonucleotide leaves the mRNA levels unaltered.
We next injected 1 ng of oligonucleotide into one
blastomere of a two-cell embryo. In Figure 4(B), loss
of eya1 mRNA was shown by in situ hybridization
where the antisense oligonucleotide injected side of
the embryo has dramatically less signal. Consistent
with the results of Schlosser et al. (2008) in Xenopus
and Zou et al. (2004, 2008) in mouse we noted
that loss of eya1 mRNA alters the expression of
other otic genes. For example, in Figure 3(B), the
side of the embryo lacking eya1 mRNA also has
reduced six1 mRNA levels. Signiﬁcant for the
present study, the expression of six1 is restored by
the injection of oligonucleotide-resistant T7-tagged
eya1 mRNA. Rescue mRNA resistance results
from replacement of several of the nucleotides
that make the endogenous mRNA complementary
to the oligonucleotide with sequence encoding the
epitope tag. The reduction of eya1 mRNA com-
promises the formation of the otocyst as shown in the
confocal sections of a stage 32 embryo (Figure 3C).
These sections show the anterior portion of the
otocyst near the top of the image and cut through the
embryo in the dorsal–lateral plane. The side of the
embryo that has reduced levels of eya1 mRNA had a
much smaller region of otic sensory tissue, no visible
neurite outgrowth (arrowheads in Figure 4) from the
sensory tissue and no visible establishment of the
VIII cranial nerve. Phalloidin staining allows the
identiﬁcation of a very small otocyst (vOt) compared
with the control non-injected side of the embryo.
As in our examination of six1 expression, normal
otocyst development was rescued using wild-type
T7-tagged eya1 mRNA. Thus the epitope-tagged
proteins used in the present study are expected to
accurately reﬂect eya1 protein activity.
Developmental consequences of injection of
mRNA encoding eya1 proteins
Our analysis of the consequences of injecting mRNA
encodingdifferenteya1proteinsassessedtoxicityand
general effects on normal development. Injection of
mRNA into one or two cell embryos can cause unin-
tendedconsequences dueto ectopic or overexpression
of protein. In Table 1 the survival of non-injected,
GFP (green ﬂuorescent protein) mRNA (used as a re-
porter of the distribution on injected material) or
embryos injected with eya1/GFP mix was tallied.
From fertilization through to stage 32, embryos in-
jected with GFP or eya1/GFP mRNA had similar
survival rates. After stage 32, embryos injected with
mutant forms of eya1 exhibited lower survival rates
and had a number of morphological defects. Com-
monlyseendefectsincludedminordelaysinreaching
stage appropriate landmarks compared with controls
(delayed development), shortened body axis and ab-
normal dorsal bending. Using stage 32 embryos to
assesstreatmentgroups,wemadeseveralcomparative
measurements to give a quantitative summary of the
defects. Table 2 shows the results of two separate tri-
als where ten embryos in each treatment group were
measured for overall length, and for three measure-
ments that focused on the embryonic head, looking
at the distance between the cement gland and the
middle of the eye, the cement gland and the ear and
the diameter of the eye.
These values were analysed using the Student’s
t test comparing non-injected embryos within each
treatment group. The analysis supported the visual
conclusionthatthreeofthemutants,G421S,R435Q
and L500R, stunted overall growth, while wild-type
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Table 2 Changes in body dimensions correlated with injection of eya1 mRNAs
Embryos from two different matings were assayed at approximately stage 32 of development. Ten embryos in each treatment group
were measured. *Average measurements with P<0.05. CG, cement gland.
Treatment Body length (mm) (S.D.) CG to eye (mm) (S.D.) CG to ear (mm) (S.D.) Eye diameter (mm) (S.D.)
Non-injected no. 1 5.50 (0.22) 0.76 (0.06) 1.27 (0.08) 0.45 (0.06)
eya1 no. 1 5.59 (0.30) 0.86 (0.08) 1.25 (0.09) 0.43 (0.04)
E358K no. 1 5.39 (0.32) 0.78 (0.10) 1.26 (0.11) 0.41 (0.05)
G421S no. 1 4.58* (0.93) 0.73 (0.11) 1.15* (0.10) 0.36* (0.03)
R435Q no. 1 4.68* (0.58) 0.76 (0.07) 1.18* (0.09) 0.41 (0.05)
L500R no. 1 4.33* (1.10) 0.77 (0.09) 1.17* (0.05) 0.36* (0.05)
Non-injected no. 2 5.43 (0.34) 0.72 (0.09) 1.17 (0.11) 0.42 (0.03)
eya1 no. 2 5.63 (0.29) 0.83* (0.05) 1.29* (0.12) 0.42 (0.04)
E358K no. 2 5.28 (0.49) 0.79 (0.07) 1.21 (0.08) 0.39* (0.05)
G421S no. 2 4.51* (0.83) 0.78 (0.09) 1.22 (0.13) 0.38* (0.04)
R435Q no. 2 4.49* (1.01) 0.78 (0.07) 1.22 (0.13) 0.40 (0.06)
L500R no. 2 4.36* (1.08) 0.71 (0.08) 1.20 (0.10) 0.38 (0.06)
eya1 and E358K did not. Not obvious on visual in-
spection, but statistically signiﬁcant in both trials,
reducedeyediameterwasseenwiththeG421Smuta-
tion. In one of the two trials, we also noted reduced
eye diameter in groups injected with the E358K and
L500R mutants. Although E358K and G421S are
associated with optical defects in humans, L500R is
not, so the relevance of this minor alteration in eye
size is unclear. In one trial there was a slight but stat-
istically signiﬁcant increase in the size of embryonic
heads (as judged from the distance from the cement
gland to the eye or ear) in embryos injected with
wild-type eya1 mRNA.
Embryos expressing eya1 mutations have
abnormal otic development
Toanalysetheinﬂuenceofmutantformsofeya1onear
development, we injected one blastomere of two-cell
embryos with mRNA encoding eya1.
Ear development was monitored by whole mount
immunohistochemistry of stage 32 (Figure 5) and
40 embryos (Figure 6) followed by confocal micro-
scopy. By stage 32 it is relatively easy to identify
the otocyst as well as the early establishment
of sensory hair cells and innervation (Figure 5;
see Supplementary Figures S1 and S2 at http://
www.biolcell.org/boc/102/boc1020277add.htm).
In Figures 5 and 6, paired images of treated em-
bryos show the non-injected side on the left and the
injected side on the right viewed along the dorsal–
lateralplaneoftheembryo.Whenembryoswereana-
lysed using phalloidin to detect F-actin, the size and
the integrity of the otic vesicle could be assessed.
Expression of eya1 or the E358K mutant did not
alter the size of the otic vesicle. However, overex-
pression of the three mutations linked to BOR res-
ulted in reduced otic vesicle size and disordered tis-
sue surrounding the vesicle (Figure 5, G421S and
L500R; and Figure 6, L500R). In some cases (Fig-
ure 5, R435Q, and Figure 6, G421S and R435Q),
no otic vesicle could be detected. Direct measure-
ments were made on 20 embryos from each treat-
mentgroup.AsshowninTable3,thedefectswerenot
completelypenetrant;approx.50%ofembryosinjec-
ted with BOR-associated mutations had otocysts at
least 10% smaller than controls. In Table 3, changes
in otocyst size were scored compared with con-
trols as normal (less than 10% different), mild (10–
30%smaller),moderate(30–50%smaller)andsevere
(>50%smaller).Notably,thelargestgroupoftheaf-
fected embryos had otocysts less than half the size of
controls.
The effect of the eya1 mutations on the develop-
ment of the sensory system was examined by detec-
tion of acetylated-α-tubulin staining. The vestibulo-
cochlear nerve (VIII cranial nerve) could be identiﬁed
in most cases, although some examples of embryos
treatedwithR435Q(Figures5and6)andG421Sand
L500R (results not shown) failed to form a detectable
VIII cranial nerve. The developing sensorial regions
of the otocyst appear as punctate staining within the
otocyst and neurite projections from sensory regions
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Figure 5 Stage 32 otic development is disrupted by eya1 mutants linked to BOR
Stage 32 embryos were imaged using a confocal microscope from the dorsal–lateral prospect. The anterior of the embryo is
towards the top of each image. Dual panels on the left show tubulin distribution; dual panels on the right detect F-actin. In each
dual set, the non-injected side (NI) of the embryo is on the left and the injected side (Inj) is on the right. Material injected into
the right side of the embryo is indicated for each row of panels. In panels detecting tubulin, the cranial nerves (VII and VIII) are
labelled when visible. The label for VIII is placed as close to the attachment to the spcd as possible. Otic sensory tissue (Ost)
is pointed out using arrows that help indicate the most anterior and posterior extents of this tissue type. Arrowheads indicate
neurites that are associated with sensory tissue and VIII. The otic vesicle (vOt) is labelled where visible on panels showing
F-actin. Scale bars, 50 μm. (Note: the right panel for non-injected controls are also shown enlarged in Figures 3E and 3G.) con,
control.
284 C   The Authors Journal compilation C   2010 Portland Press Ltd © 2010 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.Expression of EYA1 mutations in Xenopus embryos Research article
Figure 6 Stage 40 otic development is disrupted by eya1 mutants linked to BOR
Stage 40 embryos were imaged using a confocal microscope from the dorsal–lateral prospect. The anterior of the embryo is
towards the top of each image. Dual panels on the left show tubulin distribution; dual panels on the right show F-actin. In each
dual set, the non-injected side (NI) of the embryo is on the left and the injected side (Inj) is on the right. Material injected into the
right side of the embryo is indicated for each row of panels. In panels detecting tubulin the cranial nerves (VII, VIII and IX) are
labelled when visible. The label for VIII is placed as close to the attachment to the spcd as possible. Otic sensory tissue (Ost)
is pointed out using arrows that help indicate the most anterior and posterior extent of this tissue type and arrowheads show
examples of neurites connecting to the VIII nerve. The otic vesicle (vOt) is labelled where visible on panels showing F-actin.
Scale bars, 50 μm. (Note: the right panel for non-injected controls are also shown enlarged in Figures 3F and 3H). con, control.
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Table 3 Changes in otocyst dimensions correlated with injection of eya1 mRNAs
n=20. *P<0.05.
Left or non-injected Right or injected Change (%)
Treatment Average otocyst size (μm2) S.D. Average otocyst size (μm2) S.D. Normal Mild Medium Severe
Non-injected 6836 992 6880 1247 100 0 0 0
eya1 6510 2714 6576 2713 95 5 0 0
E358K 6020 1051 5961 1016 95 5 0 0
G421S 5353 844 4037* 2189 55 10 10 15
R435Q 6411 1922 4038* 2820 55 5 5 35
L500R 6053 2193 4145* 2493 50 10 10 30
were detected (arrowheads in Figures 5 and 6). For
thethreeBORmutations,therewaslessoticsensorial
tissue formation (Figures 5 and 6 and Supplement-
ary Figure S2) and some embryos (R345Q, Figures 5
and 6) had no discernible otic sensory tissue. The
reduction of sensorial tissue always correlated with
a reduction in the size of the otic vesicle. Develop-
mental defects in embryos expressing BOR mutant
protein persist, as can be seen in Figure 6 where stage
40 embryos were assayed. Thus the defects observed
at stage 32 were not simply due to delayed develop-
ment since they were not corrected when the nervous
system was assayed at stage 40.
We noted a tendency for injection of any of the
eya1 mutants to slow otic development when treated
embryos were compared with non-treated siblings
at stage 32 (Figure 5). For example, comparing the
non-injected sides of G421S, R435Q or L500R with
control embryos, the sensory patches are smaller and
neurite outgrowth is less obvious. However, for each
of these mutants, the injected side of the embryo was
signiﬁcantly more altered than the non-injected side.
The observed bilateral effect may be due to diffu-
sion of some of the injected mRNA before full mem-
braneclosureatthetwo-cellstagetothenon-injected
side. Alternatively, a few cells may have migrated
across axial boundaries during development (Wetts
and Fraser, 1989).
Expression of eya1 mutant protein reduces the
normal expression of developmentally regulated
genes
As presented above, the expression of BOR-related
mutations of eya1 leads to developmental defects.
We next examined whether the expression of mutant
proteins was reﬂected by changes in gene expres-
sion. Based on morphological observations we con-
centrated on the three mutations linked to BOR,
G421S, R435Q and L500R. First, mRNAs express-
ing the eya1 proteins were injected into one-cell
embryos. In these assays embryos were harvested at
stage25,atimeindevelopmentaftertheoticplacode
has formed but before the vesicle completely closes
at stage 27. By stage 25, under normal conditions,
the trigeminal ganglia have already formed and the
neurotrophic genes nt3 and bdnf and the neuronal
determination and differentiation genes ngnr-1 and
neuroD (Schlosser and Northcutt, 2000) are all be-
ing expressed in the developing ear. Tbx1 expres-
sion is already active in the embryo; however, expres-
sionintheeardoesnotoccuruntilstage28(Ataliotis
et al., 2005). Although these genes are not limited to
the ear, their regulated expression is critical for nor-
mal otic development. We isolated RNA from the
heads of stage 25 embryos and assayed the levels of
endogenous eya1 (endoeya1 in Table 4) expression and
levels of the other mRNAs (Table 4). None of the
mRNAs injected signiﬁcantly altered the expression
of endogenous eya1 consistent with the conclusion
that eya1 is not autoregulated. Injection of mRNA
encoding wild-type eya1 leads to increased levels of
all of the genes tested except tbx1. Conversely, ex-
pression of any of the mutants leads to a decrease in
levels of the downstream genes tested except tbx1.
We conﬁrmed the spatial effect on the expression
of key otic genes by in situ hybridization. Eya1 pro-
tein works in complex with six1 and dach. For in situ
analysis we returned to a protocol where we injec-
ted only one cell of two cell embryos, allowing the
uninjected side to serve as the control. At least 30
embryos in each treatment group were assayed. Re-
duced expression like that seen in Figure 7 was noted
in 14/30 G421S-, 15/40 R435Q- and 15/36 L500R-
treated embryos.Asimilaranalysiswasperformedon
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Table 4 QPCR analysis of selected genes in embryos injected with mRNA expressing eya1
mutant protein
Data shown were collected from three different trials, each performed in triplicate. *P<0.01.
mRNA level in treated embryos/mRNA level in control embryos
Treatment Endo eya1 NT3 NeuroD Ngn1 Tbx1 BDNF
eya1 1+ −0.3 2.8+ −0.6* 3.7+ −0.9* 3.2+ −0.5* 1+ −0.2 2.2+ −0.2*
G421S 1.2+ −0.4 0.4+ −0.1* 0.3+ −0.05* 0.3+ −0.08* 0.9+ −0.2 0.2+ −0.07*
R435Q 1.3+ −0.4 0.3+ −0.07* 0.3+ −0.1* 0.4+ −0.02* 0.9+ −0.1 0.3+ −0.2*
L500R 0.9+ −0.3 0.3+ −0.1* 0.4+ −0.02* 0.4+ −0.03* 0.8+ −0.2 0.4+ −0.09*
transcripts shown to have reduced expression by
QPCR (quantitative PCR). NeuroD expression is
shown in Figure 7 as representative of those trials.
In situ analysis shows that levels of neuroD transcripts
were reduced in the region corresponding to the de-
velopingear.Theseresultsareconsistentwiththefail-
ure to properly regulate a normal programme for otic
development when mutant eya1 protein is present.
Discussion
Examining the early developmental consequences of
genes that lead to congenital defects can be very
difﬁcult in mammalian systems. For processes where
similar developmental patterning occurs in other
organisms, a great deal can be learned by taking ad-
vantage of the experimental accessibility of those or-
ganisms.Inthesestudieswehaveusedthedeveloping
embryos of the frog X. laevis to examine the effects
of mutations in the EYA1 gene on early development
of the ear.
The work presented here took advantage of the
ease with which oligonucleotides and mRNA encod-
ingeya1oritsmutantformscouldbeintroducedinto
early embryos. Others (Zhang et al., 2004; Schlosser
et al., 2008; Zou et al., 2004, 2008) have reported
previously that loss or reduction of Eya1 protein al-
ters ear development. Consistent with their studies,
we found that oligonucleotide-directed reduction of
eya1 protein expression inhibits the formation of the
otic placode. We further showed that defects result-
ing from oligonucleotide-mediated reduction of eya1
mRNA were rescued by injection of exogenous eya1
encoding mRNA. Previous studies and ours support
the conclusion that reduced level of EYA1 protein
(i.e. haploinsufﬁciency) results in developmental ab-
normalities consistent with BOR.
The reduction trials suggest that normal levels of
eya1 protein are necessary, but are they sufﬁcient to
ensure normal otic development when mutant eya1
protein is added to the mix? We supplemented the
normal pool of eya1 mRNA with either wild-type
or mutant encoding mRNA to look for dominant-
negativeeffects.Expressionofwild-typeeya1protein
and its expression outside its usual expression do-
mains had few overt consequences. These results are
consistent with the requirement of additional tissue-
speciﬁc proteins that work with eya1 to execute its
function.Schlosser et al. (2008)reportedthatoverex-
pression of eya1 protein in early Xenopus embryos can
block the expression of differentiation genes. Close
examination of the embryos we injected with mRNA
encodingwild-typeeya1proteindetectedonlyminor
morphologicaldifferencesbetweentheseembryosand
non-injected controls. Although it is clear from our
analysis that more eya1 protein was produced from
injected mRNA than was endogenously generated,
theeya1proteinfromtheinjectedmRNAwasspread
across many tissues. In our studies we injected 250
pg of mRNA into either whole embryos or into one
cell of a two-cell embryo. If we estimate the volume
o fao n e - c e l le m b r y ot ob e1μl, the highest concen-
tration of injected mRNA in our studies would be
500 pg/μl. Schlosser et al. (2008) reported injecting
500–1000 pg into single blastomeres at the 2–16-
cell stage. Their approach would yield blastomeres
with between 2 and 64 times more eya1 mRNA than
in our studies. Thus it may not be surprising that the
expression we generated may have been below the
threshold needed for the overexpression phenotypes
noted by Schlosser et al. (2008).
How did the expression of different mutant forms
of eya1 affect development? The mildest morpholo-
gical effects were noted with the E358K mutation
where only subtle, sporadic changes in eye size and
slight developmental delays were observed. The lack
of a clear phenotype from the E358K mutation is
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Figure 7 Expression of eya1 mutations that cause BOR in humans reduces otic expression of six1, dach and neuroD
One cell of a two-cell stage embryo was injected with mRNA encoding Eya1 protein. Stage 28 embryos were assayed for
otic gene expression by in situ hybridization. In each pair of panels, the non-injected side (NI) of the embryo is shown on the
left and the side injected with mRNA (I) is on the right. The otic vesicle (vOt), facial epibranchial placode (epVII and epIX),
glossopharyngeal epibranchial placode, anterior lateral line placode (pAD), posterior lateral line placode (pP) and the eye (e) are
noted. Scale bars, 200 μm.
interesting, as in vitro studies have shown that the
E358K mutation compromised phosphatase activity
(Mutsuddiet al.,2005),failedtointeractwithSix1in
co-immunoprecipitation assays (Buller etal., 2001)
but was capable of a partial, although incomplete,
rescue of an eya-null ﬂy (Mutsuddi et al., 2005). As
in humans, our studies did not detect otic defects
with E358K. The other three mutations that were
tested are all associated with deafness and lead to
more recognizable defects. Otic development and
overall survival was compromised. We noted some
general defects including stunted growth and slowed
development that have been seen by others who have
injected a variety of mRNAs into Xenopus embryos.
These defects may be due to the toxicity related to
the amount of mRNA injected or ectopic expres-
sion of protein. However, we observed fewer defects
wheninjectingmRNAforGFP,wild-typeeya1orthe
E358K variant than when injecting mRNA for
the BOR-associated mutations. The general devel-
opmental disruptions may also have been caused by
alteration of eya1 regulation of muscle development
along the dorsal axis consistent with the roles seen
by others for Eya1 and its transcriptional partner Six
(Fougerousseet al.,2002;Grifoneet al.,2004,2007).
The consequences of the BOR-associated muta-
tionswerereadilyapparent.Inthemostobviouscases
the embryos fail to form an otocyst when mRNA-
producing mutant protein was injected. As has been
shown in other studies on Eya1 (Furuya et al., 2005;
Schlosseret al.,2008),theeffectswerenotcompletely
penetrant; however, the expression of these muta-
tions can have dramatic consequences. Notably, these
effectsoccurevenwhenembryoshavenormallevelsof
endogenous eya1 mRNA that can be translated into
protein. These ﬁndings indicate that normal levels
of wild-type eya1 are not sufﬁcient to ensure nor-
mal otic development when these BOR-associated
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proteins are also present and that the BOR muta-
tions act in a dominant-negative fashion.
Because eya1 acts with six1 and dach to regu-
late transcription, we also examined the effect of
expression of each of the mutations on a panel of
genes that have been identiﬁed as being depend-
ent on or downstream targets of Eya1 (Zou et al.,
2004; Friedman et al., 2005), including nt3, neuroD,
ngnr-1, bdnf and tbx1. Using QPCR, we analysed the
levels of mRNA that corresponds to these factors.
We showed that overexpression of wild-type eya1 in
embryos leads to up-regulation of nt3, neuroD, ngnr-1
and bdnf although morphological changes were not
evidentintheassaysweused.Itispossiblethatamore
exhaustiveanalysisofhaircellsensoryneuronsinlater
stageswouldrevealsuchchanges.Asindicatedearlier,
our results are not identical with the overexpression
results reported by Schlosser et al. (2008) who found
thatoverexpressionofeya1repressedtheexpressionof
genes required for neurogenesis and neural differen-
tiation when activated slightly later in development.
With regard to their studies and to studies on dosage
effects of Eya1 during mouse auditory development
(Zou et al., 2008), perhaps the absolute amount, the
transient nature of expression of injected mRNAs or
thedifferentstagesofdevelopmentexamined explain
someofthedifferences.Interestingly,theendogenous
expression of eya1 was not changed and tbx1 expres-
sion was also unaffected. Tbx1 expression in the ear
normally begins later than the stage we tested. Tbx1
has been reported to be activated in response to Eya1
(Friedman et al., 2005); thus the supplemented level
of eya1 that increased the expression of some genes
(nt3, neuroD, ngnr-1 and bdnf) was not sufﬁcient to
precociously activate tbx1.
All of the BOR mutant proteins resulted in lower
expression of the neurotrophins and neural differ-
entiation genes tested. However, the BOR mutant
proteins also lowered levels six1 and dach mRNA
in the otic region, indicating that the expression of
other early regulators of the developmental program
oftheearwerealsoaltered.Thereducedexpressionof
six1 protein may make a signiﬁcant contribution to
the disruption of downstream gene activation. In ad-
dition, although direct binding of eya1 and six1 may
not be needed to translocate eya1 into the nucleus
(Buller et al., 2001), in the absence of six protein,
eya1 tends to remain in the cytoplasm (Ohto et al.,
1999). Therefore one consequence of lower levels of
six1 protein may be to reduce the total amount of
eya1 protein that translocates into the nucleus.
The morphological consequences seen using
Xenopusprovidetheimpetustoreﬁnethesestudiesus-
ing some of the efﬁcient methods recently developed
togeneratetransgenicembryostomorecloselymimic
the normal levels and distribution of eya1 gene ex-
pression(AllenandWeeks,2005;Oginoet al.,2006;
Pan et al., 2006) as a rapid screen for the early devel-
opmental consequences of EYA1 mutations found in
humans.
Finally,weconcludethattherapiestocorrectEYA1
mutations are unlikely to be effective by simply
restoring levels of functional EYA1 protein to nor-
mal levels. It will be critical to also eliminate the
expression of the mutant form of the protein.
Materials and methods
Animals
X. laevis were purchased from Xenopus I (Ann Arbor, MI,
U.S.A.). Embryos were obtained after hCG (human chorionic
gonadotropin)-induced egg laying and in vitro fertilization us-
ingstandardtechniquesandstagedbythemethodofNieuwkoop
and Faber (1967). All animal protocols were reviewed and ap-
provedbytheUniversityofIowaanimalcareandusecommittee.
Oligonucleotide-mediated degradation of Eya1
Modiﬁed oligonucleotides were synthesized using H-
phosphonate chemistry on an ExpediteTM synthesizer (Applied
Biosystems, Foster City, CA, U.S.A.) (Dagle and Weeks, 2000;
Dagle et al., 2000). All reagents used for automated DNA syn-
thesis were obtained from Glen Research (Sterling, VA, U.S.A.).
To generate unmodiﬁed phosphodiester bonds, hydrogen phos-
phonate diesters were oxidized for 4 min with freshly prepared
5%iodineinTHF(tetrahydrofuran)/pyridine/water(15:2:2)and
then for 3 min with the same solution diluted 1:1 with 8%
triethylamine in THF/water (43:3). Oxidative amidation of hy-
drogen phosphonate diesters was performed manually by using
a 10% solution of DMED (Aldrich, Milwaukee, WI, U.S.A.)
in anhydrous CCl4. Further processing and puriﬁcation of oli-
gonucleotides using reverse-phase HPLC and gradient elution
with acetylnitrile as the mobile phase were performed as previ-
ously described (Dagle and Weeks, 2000; Dagle et al., 2000).
After Sephadex G-25 column chromatography, oligonucleotides
were dissolved in sterile water and quantiﬁed by UV spectro-
scopy. The sequence of the oligonucleotide used to degrade en-
dogenous eya1 mRNA was A+T+T+T+C CATAGAC
C+T+A+G+A with the sequence complementary to the 17
nucleotides surrounding the AUG (the complement of AUG is
the boldface CAT of the oligonucleotide) of the eya1 mRNA
of the GenBank® Nucleotide Sequence Database depositions
(AF352029.1 and AF352028.1 for Xenopus eya1). Frogs used for
antisenseoligonucleotidetrialswerescreenedtoensurethatthere
were no polymorphisms in the targeted area by isolating gen-
omic DNA by buccal swab followed by PCR ampliﬁcation and
sequencingofagenomicfragmentstarting109 nt5  andending
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230 nt 3  of the target sequence. Oligonucleotide effectiveness
and dose response was tested using RNA isolated from injected
embryosasasubstrateforRT–PCR(reversetranscription–PCR).
Rescueofoligonucleotideinhibitionwasaccomplishedusingthe
T7-epitope-taggedeya1mRNAdescribedbelow.TheT7tagin-
terrupts the homology sufﬁciently to render the rescue mRNA
refractory to oligonucleotide-mediated degradation.
Plasmid construction
Full-length cDNAs corresponding to Xenopus eya1 were
generated using stage 47 embryonic RNA. Eya1 cDNA
was prepared by PCR ampliﬁcation and subcloned into the
plasmid pBGFP/RN3P (Zernicka-Goetz et al., 1996), replacing
the GFP gene in the plasmid with eya1 at the EcoRI site.
The resulting plasmid was named pBEya1FLexp. Four eya1
mutations, E358K, G421S, L500R and R435Q, were generated
by PCR-based site-directed mutagenesis. Ampliﬁed fragments
were subcloned into pBEya1FLexp by replacement of the
followingrestrictionfragments.E358Kfragmentwassubcloned
between the PpuMI and NotI sites of pBEya1FLexp, G421S and
R435Q were subcloned between two BglII sites, and R435Q
was subcloned between HpaI and NotI sites. All eya1 encoding
constructs used in the present study also contain an in frame
T7 epitope at the N-terminus of the protein. pBEya1FLexp
and its derivative constructs allow in vitro expression of eya1
mRNA using T3 polymerase. All constructs were conﬁrmed
by sequencing and by in vitro transcription/translation using a
coupled transcription translation system (the TNT system and
restriction enzymes were purchased from Promega, Madison,
WI, U.S.A.) followed by Western-blot analysis.
Embryo culture and microinjection
Capped mRNA of full-length eya1 or eya1 mutations were
generated in vitro using the mMessage Machine T3 transcription
kit (Ambion). All eya1 encoding plasmids were linearized with
SﬁI for in vitro transcription. mRNA was injected into a one-cell
embryo or one blastomere of two-cell embryos. A 10 nl portion
of the solution containing 25 pg/nl of mRNA was injected
in each embryo. GFP mRNA (100 pg/nl) was co-injected as a
tracer in experiments where one blastomere of a two-cell embryo
was injected. Embryos were grown to the desired stage at 18◦C.
Embryos co-injected with GFP mRNA were pre-sorted
according to whether GFP expression was restricted to the left
or right side.
Whole mount immunohistochemistry
Detailed methods can be found in Kolker et al. (2000) and
Bane et al. (2005) but, brieﬂy, Xenopus embryos were ﬁxed in
Dent’s ﬁxative [80% (v/v) methanol and (v/v) 20% DMSO] and
stored at –20◦C until processed. Rehydrated specimens were
rinsed in PBS-DT (PBS, 1% Tween 20, 1% DMSO and 0.02%
NaN3), and blocked with PBS-DT with 0.1 M glycine, 2%
(w/v) non-fat dried skimmed milk powder and 1% BSA for
4 h at room temperature (22◦C). The primary antibody, anti-
acetylated α-tubulin (6-11B-1; Sigma, St. Louis, MO, U.S.A.),
was diluted 1:50 with the block solution. Incubation with the
primary antibody was carried out overnight at 4◦C. Samples
were rinsed ten times over 8 h with PBS-DT. The secondary an-
tibody, anti-mouse IgG2b (Sigma), was diluted 1:200 in block
solution and allowed to incubate overnight at 4◦C. Samples
were rinsed as described for primary antibody treatment and
subsequently dehydrated in an ethanol series. For double la-
belling with phalloidin, embryos were rinsed in methanol, and
incubated for 5 h in 3.3 μM phalloidin–FITC (Sigma) diluted
in methanol. Embryos were then rinsed twice in methanol and
stored overnight at –20◦C. Whole mount embryos were viewed
on a Bio-Rad MRC-1024 confocal microscope (Bio-Rad, Her-
cules,CA,U.S.A.)equippedwithakrypton/argonlaser.Confocal
Assistant 4.02, ImageJ and Adobe Photoshop 7.0 were used for
image processing.
In situ hybridization
In situ hybridization was carried out essentially as described by
Harland (1991). Embryos were ﬁxed at the appropriate stage
of development using MEMFA (0.1 M Mops, 2 mM EGTA,
1m MM g S O 4 and 0.4% paraformaldehyde) and rehydrated in
TTW (200 mM NaCl, 50 mM Tris, pH 7.4, and 0.1% Tween
20). DIG (digoxigenin)-labelled probes for eya1, six1, dach and
neuroD were generated from plasmids containing cDNAs of
these transcripts using an Ambion Megascript kit with DIG
RNA labelling mix. Probes were hybridized with ﬁxed em-
bryos using hybridization buffer [50% formamide, 5 SSC (1×
SSC is 0.15 M NaCl/0.015 M sodium citrate), 1 mg/ml total
yeast RNA, 1× Denhardt’s, 0.1% Tween 20 and 5 mM EDTA]
and, after extensive washing in 0.2 × SSC, were incubated with
alkaline phosphatase-conjugated anti-DIG antibody (1:5000;
Roche) in MAB [100 mM maleic acid, 150 mM NaCl, pH 7.5,
and0.02 g/mlBMBR(BoehringerMannheim)blockingreagent
(Roche, Mannheim, Germany)] overnight at 4◦C. After extens-
ive washing at room temperature with 100 mM Tris (pH 9.5),
50 mM MgCl2, 100 mM NaCl, 0.1% Tween 20 and 1 mM
levamisol to remove unbound antibody, colorimetric detection
of hybrids was accomplished using 0.3 mg/ml of Nitro Blue
Tetrazolium and 0.2 mg/ml of BCIP (5-bromo-4-chloroindol-
3-yl phosphate) in the washing solution. Colour reactions were
stopped using 100% methanol.
Western blotting
Protein extracts were made by homogenization of fresh Xenopus
embryos using 20 μl of homogenization buffer (0.1 M NaCl,
1% Triton X-100, 1 mM PMSF and 20 mM Tris/HCl, pH 7.6)
per embryo. Protein extracts were mixed with bromoacet-
ate (ﬁnal concentration 0.067 M) prior to separation on SDS
gels. Protein extracted from two embryos was loaded on to
each well of a 4–20% precast gel (Bio-Rad). Protein was
transferred from gels to nitrocellulose membranes using semi-
dry transfer (Owl, Cambridge, MA, U.S.A.). Membranes were
blocked using 10% non-fat dried skimmed milk powder in
TBS (20 mM Tris, pH 7.6, and 0.137 M NaCl) for at least
4 h at room temperature. T7. Tag antibody (1:5000; Novagen,
EMD Chemicals, Gibbstown, NJ, U.S.A.) or eya1 antibody
(1:2000, guinea-pig anti-Xenopus eya1, a gift from Dr Ger-
hard Schlosser) were used as primary antibodies. Anti-mouse
IgG1 HRP (horseradish peroxidase; 1:2000, Sigma) was used
as a secondary antibody for T7.Tag antibody and anti-guinea-
pig IgG HRP (1:2000; Sigma) for eya1 antibody. The pres-
ence of eya1 protein was detected using an ECL (enhanced
chemiluminescence; SuperSignal West Pico Chemiluminescent
Substrate; Pierce, Rockford, IL, U.S.A.) reaction. When (in
Figure 2) Adobe Photoshop was used to reorder lanes from a
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single gel after digital capture, the reordered lanes were separ-
ated by a clear break.
Statistical analysis
Treated embryos were measured for body length, distance
between the cement gland and the eye, the cement gland and
the ear and the diameter of the eye. Values for each treatment
group were compared with the non-injected controls using the
Student’s t test (two-tailed, assuming two-sample equal vari-
ance). Confocal analysis through the dorsal–ventral axis identi-
ﬁed and measured the widest diameter of the otocyst. Average
otocyst size for each treatment group was used to calculate sig-
niﬁcant variation using a paired, two-tailed Student’s t test.
Single embryo analysis separated BOR-causing mutations into
four groups: non-affected (less than 10% difference), mild (10–
30% difference in otocyst size), moderate (30–50% difference in
otocyst size) and severe (>50% difference in otocyst size).
Quantitative RT–PCR
RNA isolated from the heads of stage 25 embryos was used
for quantitative RT–PCR analysis. Embryonic heads were sep-
arated from the rest of the embryo by cutting just posterior
from the otic vesicle and ventrally in front of the devel-
oping gut. Fresh tissue was placed in RNAlater (Ambion,
Austin, TX, U.S.A.) and stored overnight at 4◦C. Total RNA
was isolated by using an RNAqueous isolation kit (Ambion).
The kit incorporates a DNase step to ensure that isolated RNA
is DNA-free. Approx. 300 ng of total RNA was isolated per
head. We used 1 μg of total RNA to make cDNA in a total
reaction volume of 20 μl. The cDNA reaction was diluted 5-
fold to 100 μl. A 5 μl portion of diluted cDNA was assayed
in triplicate for each QPCR. Sequences selected for analysis by
QPCR were: tbx1, bdnf, nt3, neuroD and ngnr-1. Primers for real-
time PCR were designed using Primer 3 software. Ampliﬁed
cDNA fragment sizes ranged between 50 and 250 bp and were
tested prior to QPCR analysis to ensure that they generated a
single ampliﬁcation product. Sequences for primers were iden-
tiﬁed from GenBank® at NCBI (National Center for Biotech-
nology Information). Primers used were: endogenous eya1:f o r -
ward: cgatggctggagggttat, reverse: gtctactatgtgggctggcta; total
eya1:forward:cctaccccttcttcccaaac,reverse:atccaccttccgtcttgatg;
nt3: forward: aagcaacggcgatacaaatc, reverse: tacaagggaggag-
gttccaa; tbx1: forward: gctaaaggggctcagtggat, reverse: tg-
gagttcaggatgatgtgg; ngnr-1: forward: gctgctgaagtgcgaatacc, re-
verse:gtgaagaggaggaggacacg;neuroD:forward:atgaaggggatgag-
gaggag, reverse: cttttgggtttctggtcgtc; bdnf:f o r w a r d :g c a t a g g t -
ggtctcggtgtc, reverse: cttgctttcctcgctctgtc; 28S rRNA: forward:
ggtgttgacgcgatgtgatttctg, reverse: tagatgacgaggcatttggcatcc.
To determine relative gene expression, the Ct (threshold cycle
value) of each candidate was normalized to the Ct of the PCR
product for the housekeeping gene 28S rRNA. QPCR was per-
formedina96-wellformatusingPowerSYBRGreenMasterMix
(AppliedBiosystems)ona7500RealTimePCRsystem(Applied
Biosystems). All the reactions were done in triplicate. Reaction
conditionsusedwereasfollows:stage1:50◦Cfor2 min;stage2:
95◦C for 10 min; stage 3; 95◦C for 15 s, 60◦Cf o r1m i n .S t a g e
3 was repeated for 40 cycles. Fold changes between treatment
groups and non-injected controls were analysed using a two-
tailed Student’s t test.
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EYA1 mutations associated with the branchio-oto-renal
syndrome result in defective otic development in Xenopus
laevis
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Figure S1 Whole mount imaging of the otic region of a stage 34 embryo
Images were captured starting from the left lateral side of the embryo and then moving medially. (A) A composite of stacks (B)
and (C). (B) Each image of a confocal stack using phalloidin as a stain. (C) Each image of a confocal stack detecting acetylated
α-tubulin. Enlargements of companion images show how phalloidin staining highlights the otocyst and allows an easy estimate
of otic vesicle (vOt) size. The otic vesicle is coloured red in B 5. The appearance of sensory tissue in the otocyst (Ost) can be
seen in C 5 and C 8 by reactivity to the anti-tubulin antibody and are selectively coloured green. In C 11 the neurites (arrowheads)
connecting the VIII cranial nerve with the otocyst on the ventral medial side are coloured green. Scale bar in (A), 50 μm. An,
anterior; D, dorsal; Pos, posterior; V, ventral; VII, VII cranial nerve.
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Figure S2 Whole mount imaging of the otic region of a stage 34 embryo that is expressing R435Q on its right side
Images were captured starting from the dorsal-lateral area of the embryo and then moving in the ventral-medial direction. (A)A
composite of stacks (B)a n d( C). (D) is a composite stack of (E)a n d( F). (B, E) Each image of a confocal stack using phalloidin.
(C, F) Each image of a confocal stack detecting acetylated α-tubulin. Enlargements of companion images show how phalloidin
staining highlights the otocyst (Ost) and allows an easy estimate of otic vesicle (vOt) size. The otic vesicle is coloured red in B
5 and E 5. The appearance of sensory tissue in the otocyst (Ost) can be seen in C and F 2, 5 and 8, with the greyscale image
selectively inverted in C and F 5 and 11 with the inverted image showing sensory tissue as black. The position of the VII cranial
nerve is indicated in C 8. In C 11 the neurites (arrowheads) between the sensory tissue and the VIII cranial nerve with the otocyst
on the ventral medial side are detected in C but are barely visible in F. Arrowheads point to neurites associated with sensorial
tissue and the VIII cranial nerve. Scale bars in (C)a n d( F), 50 μm.
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